Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older.
- You have been diagnosed with a specific type of Myasthenia Gravis (a muscle weakness disease) that affects multiple parts of the body and has tested positive for a particular antibody called anti-AChR.
- Your doctor has determined that you need treatment with a specific type of medication called an FcRn inhibitor, based on approved medical guidelines.
- You are able to attend regular follow-up appointments at the specialist centre running the trial.
- You are willing and able to sign a consent form agreeing to take part in the study.
Who may not be able to join:
- You are under 18 years old.
- You have had difficulty following or sticking to prescribed medication schedules in the past.
- You have another autoimmune disease (a condition where your immune system attacks your own body) at the same time.
- There is not enough medical information available about your health history.
- You currently have an active cancer or an ongoing infection at the time your biological samples (such as blood) would be collected.
- You do not wish to sign the consent form for the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Raffaele Iorio, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +390630154807
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identification of Clinical Markers of Favorable Response to FcRn Inhibitors Therapy in Patients With Generalized Myasthenia Gravis; Identification of Biological and Cellular Markers of Favorable Response to FcRn Inhibitors Therapy in Patients With Generalized Myasthenia Gravis; Identification of Biological and Cellular Markers of Favorable Response to FcRn Inhibitors Therapy in Patients With Generalized Myasthenia Gravis; Identification of Biological and Cellular Markers of Favorable Response to FcRn Inhibitors Therapy in Patients With Generalized Myasthenia Gravis; Identification of Genetic M...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.